Literature DB >> 31779513

Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies.

Cholpon Tilegenova1, Saeed Izadi2, Jianping Yin3, Christine S Huang4, Jiansheng Wu4, Diego Ellerman4, Sarah G Hymowitz3, Benjamin Walters5, Cleo Salisbury2, Paul J Carter1.   

Abstract

Some antibodies exhibit elevated viscosity at high concentrations, making them poorly suited for therapeutic applications requiring administration by injection such as subcutaneous or ocular delivery. Here we studied an anti-IL-13/IL-17 bispecific IgG4 antibody, which has anomalously high viscosity compared to its parent monospecific antibodies. The viscosity of the bispecific IgG4 in solution was decreased by only ~30% in the presence of NaCl, suggesting electrostatic interactions are insufficient to fully explain the drivers of viscosity. Intriguingly, addition of arginine-HCl reduced the viscosity of the bispecific IgG4 by ~50% to its parent IgG level. These data suggest that beyond electrostatics, additional types of interactions such as cation-π and/or π-π may contribute to high viscosity more significantly than previously understood. Molecular dynamics simulations of antibody fragments in the mixed solution of free arginine and explicit water were conducted to identify hotspots involved in self-interactions. Exposed surface aromatic amino acids displayed an increased number of contacts with arginine. Mutagenesis of the majority of aromatic residues pinpointed by molecular dynamics simulations effectively decreased the solution's viscosity when tested experimentally. This mutational method to reduce the viscosity of a bispecific antibody was extended to a monospecific anti-GCGR IgG1 antibody with elevated viscosity. In all cases, point mutants were readily identified that both reduced viscosity and retained antigen-binding affinity. These studies demonstrate a new approach to mitigate high viscosity of some antibodies by mutagenesis of surface-exposed aromatic residues on complementarity-determining regions that may facilitate some clinical applications.

Entities:  

Keywords:  Bispecific IgG; IgG; viscosity

Mesh:

Substances:

Year:  2020        PMID: 31779513      PMCID: PMC6927759          DOI: 10.1080/19420862.2019.1692764

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  59 in total

Review 1.  Challenges in the development of high protein concentration formulations.

Authors:  Steven J Shire; Zahra Shahrokh; Jun Liu
Journal:  J Pharm Sci       Date:  2004-06       Impact factor: 3.534

2.  Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies.

Authors:  Sandeep Yadav; Steven J Shire; Devendra S Kalonia
Journal:  J Pharm Sci       Date:  2010-12       Impact factor: 3.534

Review 3.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

4.  Small-scale screening method for low-viscosity antibody solutions using small-angle X-ray scattering.

Authors:  Masakazu Fukuda; Atsushi Watanabe; Akira Hayasaka; Masaru Muraoka; Yuji Hori; Tadao Yamazaki; Yoshimi Imaeda; Akiko Koga
Journal:  Eur J Pharm Biopharm       Date:  2016-11-24       Impact factor: 5.571

5.  A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies.

Authors:  Reza Esfandiary; David B Hayes; Arun Parupudi; Jose Casas-Finet; Shufeng Bai; Hardeep S Samra; Ambarish U Shah; Hasige A Sathish
Journal:  J Pharm Sci       Date:  2012-11-13       Impact factor: 3.534

6.  Parallel temperature-dependent microrheological measurements in a microfluidic chip.

Authors:  Lilian Lam Josephson; William J Galush; Eric M Furst
Journal:  Biomicrofluidics       Date:  2016-06-14       Impact factor: 2.800

7.  Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.

Authors:  Andrew G Polson; Shang-Fan Yu; Kristi Elkins; Bing Zheng; Suzanna Clark; Gladys S Ingle; Dionysos S Slaga; Lynne Giere; Changchun Du; Christine Tan; Jo-Anne Hongo; Alvin Gogineni; Mary J Cole; Richard Vandlen; Jean-Philippe Stephan; Judy Young; Wesley Chang; Suzie J Scales; Sarajane Ross; Dan Eaton; Allen Ebens
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

8.  Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab.

Authors:  Mark Ultsch; Jack Bevers; Gerald Nakamura; Richard Vandlen; Robert F Kelley; Lawren C Wu; Charles Eigenbrot
Journal:  J Mol Biol       Date:  2013-01-25       Impact factor: 5.469

9.  Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys.

Authors:  Kay Stubenrauch; Uwe Wessels; Joerg Thomas Regula; Hubert Kettenberger; Julia Schleypen; Ulrich Kohnert
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

10.  In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation.

Authors:  Bing Li; Ashley E Fouts; Katharina Stengel; Peng Luan; Michael Dillon; Wei-Ching Liang; Becket Feierbach; Robert F Kelley; Isidro Hötzel
Journal:  MAbs       Date:  2014-01-16       Impact factor: 5.857

View more
  9 in total

1.  Multiscale Coarse-Grained Approach to Investigate Self-Association of Antibodies.

Authors:  Saeed Izadi; Thomas W Patapoff; Benjamin T Walters
Journal:  Biophys J       Date:  2020-04-29       Impact factor: 4.033

Review 2.  Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies.

Authors:  Rahmad Akbar; Habib Bashour; Puneet Rawat; Philippe A Robert; Eva Smorodina; Tudor-Stefan Cotet; Karine Flem-Karlsen; Robert Frank; Brij Bhushan Mehta; Mai Ha Vu; Talip Zengin; Jose Gutierrez-Marcos; Fridtjof Lund-Johansen; Jan Terje Andersen; Victor Greiff
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

3.  DeepSCM: An efficient convolutional neural network surrogate model for the screening of therapeutic antibody viscosity.

Authors:  Pin-Kuang Lai
Journal:  Comput Struct Biotechnol J       Date:  2022-04-29       Impact factor: 6.155

4.  Toward Biotherapeutics Formulation Composition Engineering using Site-Identification by Ligand Competitive Saturation (SILCS).

Authors:  Sandeep Somani; Sunhwan Jo; Renuka Thirumangalathu; Danika Rodrigues; Laura M Tanenbaum; Ketan Amin; Alexander D MacKerell; Santosh V Thakkar
Journal:  J Pharm Sci       Date:  2020-11-01       Impact factor: 3.784

5.  Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters.

Authors:  Pin-Kuang Lai; James W Swan; Bernhardt L Trout
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

6.  Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics.

Authors:  Nels Thorsteinson; John R Gunn; Kenneth Kelly; Will Long; Paul Labute
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

7.  Development of QSAR models for in silico screening of antibody solubility.

Authors:  Xuan Han; James Shih; Yuhao Lin; Qing Chai; Steven M Cramer
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

8.  A single molecular descriptor to predict solution behavior of therapeutic antibodies.

Authors:  Jonathan S Kingsbury; Amandeep Saini; Sarah Marie Auclair; Li Fu; Michaela M Lantz; Kevin T Halloran; Cesar Calero-Rubio; Walter Schwenger; Christian Y Airiau; Jifeng Zhang; Yatin R Gokarn
Journal:  Sci Adv       Date:  2020-08-05       Impact factor: 14.136

Review 9.  Toward Drug-Like Multispecific Antibodies by Design.

Authors:  Manali S Sawant; Craig N Streu; Lina Wu; Peter M Tessier
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.